Calls for papers
-
According to AstraZeneca, it has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its Fluenz Tetra intranasal four-strain live attenuated influenza vaccine developed by its MedImmune subsidiary.… Read more . . .
-
Avanir Pharmaceuticals has published results of a pharmacokinetic study of its AVP-825 intranasal sumatriptan powder for the treatment of acute migraine. Avanir licensed AVP-825 from OptiNose in July 2013, and the powder is delivered using… Read more . . .
-
Sosei Group and Vectura have announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Ultibro glycopyrronium/indacaterol inhalation capsules, which are delivered using the Breezhaler DPI, for treatment of COPD. Ultibro, also… Read more . . .
-
GlaxoSmithKline and Theravance have announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI for the treatment of asthma… Read more . . .
-
A Phase 3 trial of Flutiform fluticasone propionate/formoterol fumarate MDI for the treatment of COPD has been initiated, according Mundipharma. The 52-week randomized, double-blind EFFECT study compare Flutiform 250/10 μg and Flutiform 125/5 μg with… Read more . . .
-
Medivir AB has entered into a license agreement with Ferrer for exclusive rights to commercialize Adasuve inhaled loxapine in Denmark, Finland, Norway, Iceland and Sweden. The company is paying Ferrer an undisclosed amount up front,… Read more . . .
-
The US Patent and Trademark Office (USPTO) has issued notices of allowance for two Mystic Pharmaceuticals patents related to its VersiDoser and VRx2 intranasal delivery platforms. The VersiDoser platform is used for packaging and aerosol… Read more . . .
-
According to the Allergy & Asthma Network Mothers of Asthmatics (AANMA), President and Founder Nancy Sander has retired. Sander founded the patient advocacy organization in 1985. Over the course of her tenure with AANMA, Sander… Read more . . .
-
Chiesi Farmaceutici will acquire all outstanding shares of Cornerstone Therapeutics for $9.50 per share, the companies have announced. Chiesi already owns almost 60% of Cornerstone outstanding common shares. Cornerstone announced in February 2013 that it… Read more . . .
-
Sigma-Tau PharmaSource and Aradigm have announced that Sigma-Tau PharmaSource will provide clinical and commercial manufacturing services for Aradigm’s Pulmaquin inhaled ciprofloxacin. Pulmaquin is in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis. Terms… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden